Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock Award Plans (Tables)

Stock Award Plans (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of stock-based compensation expense related to all of the entity's stock-based awards

Total stock-based compensation expense related to all of our stock-based awards that we recognized was as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Research and development	$	1,035	$	1,866	$	3,060	$	5,213
General and administrative	789		1,379		2,304		4,141
Restructuring charges	239		—		239		—
Total stock-based compensation expense	$	2,063	$	3,245	$	5,603	$	9,354

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Equity Incentive Plans				Equity Incentive Plans
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Risk-free interest rate	1.5	%	0.7	%	1.0	%	0.9	%
Expected term (in years)	5.0		5.0		5.4		5.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	69.5	%	83.9	%	72.5	%	81.6	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Employee Stock Purchase Plan
	Nine Months Ended
	September 30,
	2013		2012
Risk-free interest rate	0.2	%	0.2	%
Expected term (in years)	1.4		1.2
Dividend yield	0.0	%	0.0	%
Expected volatility	64.4	%	47.3	%

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details